EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zhejiang Ausun Pharmaceutical Co's enterprise value is ¥5,170.2 Mil.
Zhejiang Ausun Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was ¥316.9 Mil. Therefore, Zhejiang Ausun Pharmaceutical Co's EV-to-EBITDA for today is 16.32.
The historical rank and industry rank for Zhejiang Ausun Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
SHSE:603229'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 14.57 Med: 41.23 Max: 180.37
Current: 15.72
During the past 11 years, the highest EV-to-EBITDA of Zhejiang Ausun Pharmaceutical Co was 180.37. The lowest was 14.57. And the median was 41.23.
SHSE:603229's EV-to-EBITDA is ranked worse than 64.19% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs SHSE:603229: 15.72
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Zhejiang Ausun Pharmaceutical Co's stock price is ¥9.99.
Zhejiang Ausun Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was ¥0.491. Therefore, Zhejiang Ausun Pharmaceutical Co's PE Ratio for today is 20.35.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Zhejiang Ausun Pharmaceutical Co EV-to-EBITDA Historical Data
The historical data trend for Zhejiang Ausun Pharmaceutical Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zhejiang Ausun Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Ausun Pharmaceutical Co EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Zhejiang Ausun Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zhejiang Ausun Pharmaceutical Co's EV-to-EBITDA falls into.
Zhejiang Ausun Pharmaceutical Co EV-to-EBITDA Calculation
Zhejiang Ausun Pharmaceutical Co's EV-to-EBITDA for today is calculated as:
Zhejiang Ausun Pharmaceutical Co's current Enterprise Value is ¥5,170.2 Mil.
Zhejiang Ausun Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥316.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Zhejiang Ausun Pharmaceutical Co's PE Ratio for today is calculated as:
Zhejiang Ausun Pharmaceutical Co's share price for today is ¥9.99.
Zhejiang Ausun Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.491.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Zhejiang Ausun Pharmaceutical Co EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Zhejiang Ausun Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Business Description
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:603229 has been successfully added to your 